Public Citizen calls for halt to prasugrel review
04 June 2009
Alex Shimmings
The US
FDA's review of
Lilly/
Daiichi Sankyo 's novel antiplatelet therapy prasugrel (Effient) should be halted until a new Phase III study looking at a lower, safer dose has been performed,
Public Citizen's Health Research Group has urged the new FDA commissioner
Dr Margaret Hamburg.
In a...
Please Login to read the full article.
04 June 2009
Alex Shimmings
In a...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: New York Democratic win exposes vulnerability of tampering with Medicare
- Astellas' darexaban in ACS – value far above RUBY-1?
- US Capitol Capsule: IOM analysis finds little evidence of vaccine harm, debunks autism link
- US Capitol Capsule: FDA's CDER ends 2011 with 30 new drugs and biologics
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
